A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
出版年份 2021 全文链接
标题
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
作者
关键词
-
出版物
Alzheimers Research & Therapy
Volume 13, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-04-17
DOI
10.1186/s13195-021-00813-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain
- (2020) Cyrille Sur et al. BRAIN
- Specific Uptake of an Amyloid-β Protofibril-Binding Antibody-Tracer in AβPP Transgenic Mouse Brain
- (2018) Kristina Magnusson et al. JOURNAL OF ALZHEIMERS DISEASE
- The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice
- (2018) Stina Tucker et al. JOURNAL OF ALZHEIMERS DISEASE
- Neurofilaments as biomarkers in neurological disorders
- (2018) Michael Khalil et al. Nature Reviews Neurology
- Current state of Alzheimer’s fluid biomarkers
- (2018) José Luis Molinuevo et al. ACTA NEUROPATHOLOGICA
- A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
- (2017) Susanne Ostrowitzki et al. Alzheimers Research & Therapy
- ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
- (2016) Jinping Wang et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
- (2016) Veronika Logovinsky et al. Alzheimers Research & Therapy
- Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease
- (2012) Henrik Zetterberg ARCHIVES OF NEUROLOGY
- Large Aggregates Are the Major Soluble Aβ Species in AD Brain Fractionated with Density Gradient Ultracentrifugation
- (2012) Dag Sehlin et al. PLoS One
- Polymorphic Structures of Alzheimer's β-Amyloid Globulomers
- (2011) Xiang Yu et al. PLoS One
- Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer’s disease
- (2010) Delphine Boche et al. ACTA NEUROPATHOLOGICA
- Amyloid -Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils
- (2010) B. O'Nuallain et al. JOURNAL OF NEUROSCIENCE
- Revising the definition of Alzheimer's disease: a new lexicon
- (2010) Bruno Dubois et al. LANCET NEUROLOGY
- Amyloid-β Oligomers: Possible Roles as Key Neurotoxins in Alzheimer's Disease
- (2010) Alex L. Lublin et al. MOUNT SINAI JOURNAL OF MEDICINE
- Heavy-Chain Complementarity-Determining Regions Determine Conformation Selectivity of Anti-Aβ Antibodies
- (2010) Dag Sehlin et al. Neurodegenerative Diseases
- Is passive immunization for Alzheimer's disease ‘alive and well’ or ‘dead and buried’?
- (2009) Gregory A Jicha EXPERT OPINION ON BIOLOGICAL THERAPY
- An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease
- (2009) Anna Lord et al. NEUROBIOLOGY OF DISEASE
- Molecular structural basis for polymorphism in Alzheimer's -amyloid fibrils
- (2008) A. K. Paravastu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search